Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 11/2020

13.06.2020 | Brief Report

A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli

verfasst von: Taylor Morrisette, Abdalhamid M. Lagnf, Sara Alosaimy, Michael J. Rybak

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

The use of daptomycin (DAP) in septic pulmonary emboli (SPE) remains controversial. We analyzed 29 cases of MRSA bacteremia complicated by SPE treated with DAP (n = 14) or DAP-ceftaroline fosamil (CPT; n = 15). Initial treatment with DAP monotherapy was found to have a success rate comparable with DAP-CPT (71% vs. 80%; p = 0.68).
Literatur
2.
Zurück zum Zitat van Hal SJ, Fowler VG Jr (2013) Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56:1779–1788CrossRef van Hal SJ, Fowler VG Jr (2013) Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56:1779–1788CrossRef
3.
Zurück zum Zitat Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN (2014) Associations and outcomes of septic pulmonary emboli. Open Respir Med J 8:28–33CrossRef Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN (2014) Associations and outcomes of septic pulmonary emboli. Open Respir Med J 8:28–33CrossRef
4.
Zurück zum Zitat Silverman JA, Mortin LE, VanPraagh ADG, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149–2152CrossRef Silverman JA, Mortin LE, VanPraagh ADG, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149–2152CrossRef
5.
Zurück zum Zitat Crass RL, Powell KL, Huang AM (2019) Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis 93:131–135CrossRef Crass RL, Powell KL, Huang AM (2019) Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis 93:131–135CrossRef
6.
Zurück zum Zitat Wong D, Chandraratna AN, Wishnow RM, Dusitnanond V, Nimalasuriya A (1983) Clinical implications of large vegetations in infectious endocarditis. Arch Intern Med 143:1874–1877CrossRef Wong D, Chandraratna AN, Wishnow RM, Dusitnanond V, Nimalasuriya A (1983) Clinical implications of large vegetations in infectious endocarditis. Arch Intern Med 143:1874–1877CrossRef
7.
Zurück zum Zitat Rehm SJ, Boucher H, Levine D et al (2008) Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62:1413–1421CrossRef Rehm SJ, Boucher H, Levine D et al (2008) Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62:1413–1421CrossRef
8.
Zurück zum Zitat Kanafani Z, Boucher H, Fowler V et al (2010) Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin 28:498–503CrossRef Kanafani Z, Boucher H, Fowler V et al (2010) Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin 28:498–503CrossRef
9.
Zurück zum Zitat Werth BJ, Sakoulas G, Rose WE, Pgliano J, Tewhey R, Rybak MJ (2013) Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 57:66–73CrossRef Werth BJ, Sakoulas G, Rose WE, Pgliano J, Tewhey R, Rybak MJ (2013) Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 57:66–73CrossRef
10.
Zurück zum Zitat Geriak M, Haddad F, Rizvi K et al (2019) Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.02483-18 Geriak M, Haddad F, Rizvi K et al (2019) Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63. https://​doi.​org/​10.​1128/​AAC.​02483-18
11.
Zurück zum Zitat Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665CrossRef Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665CrossRef
12.
Zurück zum Zitat Harada Y, Yanagihara K, Yamada K et al (2013) In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection. Antimicrob Agents Chemother 57:2841–2844CrossRef Harada Y, Yanagihara K, Yamada K et al (2013) In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection. Antimicrob Agents Chemother 57:2841–2844CrossRef
13.
Zurück zum Zitat Kephart PA, Esposito AL (1988) Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 21:33–39CrossRef Kephart PA, Esposito AL (1988) Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 21:33–39CrossRef
14.
Zurück zum Zitat Verghese A, Haire C, Franzus B, Smith K (1988) LY146032 in a hamster model of Staphylococcus aureus pneumonia—effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy 34:497–503CrossRef Verghese A, Haire C, Franzus B, Smith K (1988) LY146032 in a hamster model of Staphylococcus aureus pneumonia—effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy 34:497–503CrossRef
15.
Zurück zum Zitat Heine HS, Basset J, Miller L, Purcell BK, Byrne WR (2010) Efficacy of daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation. Antimicrob Agents Chemother 54:4471–4473CrossRef Heine HS, Basset J, Miller L, Purcell BK, Byrne WR (2010) Efficacy of daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation. Antimicrob Agents Chemother 54:4471–4473CrossRef
16.
Zurück zum Zitat Pertel PE, Bernardo P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy on daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151CrossRef Pertel PE, Bernardo P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy on daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151CrossRef
17.
Zurück zum Zitat Hagiya H, Hagioka S, Otsuka F (2013) Ineffectiveness of daptomycin in the treatment of septic pulmonary emboli and persistent bacteremia caused by methicillin-resistant Staphylococcus aureus. Intern Med 52:2577–2582CrossRef Hagiya H, Hagioka S, Otsuka F (2013) Ineffectiveness of daptomycin in the treatment of septic pulmonary emboli and persistent bacteremia caused by methicillin-resistant Staphylococcus aureus. Intern Med 52:2577–2582CrossRef
Metadaten
Titel
A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli
verfasst von
Taylor Morrisette
Abdalhamid M. Lagnf
Sara Alosaimy
Michael J. Rybak
Publikationsdatum
13.06.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-03941-5

Weitere Artikel der Ausgabe 11/2020

European Journal of Clinical Microbiology & Infectious Diseases 11/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.